ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 165 filers reported holding ABCELLERA BIOLOGICS INC in Q2 2022. The put-call ratio across all filers is 0.40 and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $458,125 | +2.3% | 154,772 | +56.5% | 0.00% | – |
Q1 2024 | $447,949 | -67.8% | 98,885 | -59.4% | 0.00% | – |
Q4 2023 | $1,390,043 | +169.6% | 243,440 | +117.2% | 0.00% | – |
Q3 2023 | $515,624 | -41.8% | 112,092 | -18.3% | 0.00% | – |
Q2 2023 | $886,609 | +139.4% | 137,246 | +179.4% | 0.00% | – |
Q1 2023 | $370,380 | +84.0% | 49,122 | +147.2% | 0.00% | – |
Q4 2022 | $201,293 | -18.8% | 19,871 | -20.8% | 0.00% | – |
Q3 2022 | $248,000 | -43.9% | 25,101 | -39.5% | 0.00% | – |
Q2 2022 | $442,000 | -95.8% | 41,502 | -96.2% | 0.00% | -100.0% |
Q1 2022 | $10,510,000 | -44.8% | 1,078,000 | -19.1% | 0.00% | -50.0% |
Q4 2021 | $19,048,000 | -33.5% | 1,331,946 | -6.8% | 0.01% | -40.0% |
Q3 2021 | $28,640,000 | +96.1% | 1,429,157 | +115.3% | 0.01% | +66.7% |
Q2 2021 | $14,605,000 | +800.4% | 663,921 | +1289.9% | 0.01% | +500.0% |
Q1 2021 | $1,622,000 | +169.9% | 47,767 | +220.1% | 0.00% | – |
Q4 2020 | $601,000 | – | 14,923 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Founders Fund VII Management, LLC | 3,773,530 | $28,452,416 | 91.13% |
Founders Fund Growth Management, LLC | 407,017 | $3,068,908 | 14.23% |
Gruss & Co., LLC | 167,500 | $1,262,950 | 7.99% |
HARVARD MANAGEMENT CO INC | 4,105,095 | $30,952,416 | 3.25% |
Belmont Capital, LLC | 510,000 | $3,845,400 | 3.18% |
Prosight Management, LP | 753,528 | $5,681,601 | 2.69% |
Intellectus Partners, LLC | 872,483 | $6,578,520 | 2.08% |
Casdin Capital, LLC | 2,520,000 | $19,000,800 | 1.56% |
GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $13,022,958 | 1.50% |
Orbimed Advisors | 4,180,768 | $31,522,991 | 0.62% |